SCHEMBL5823723

SCHEMBL5823723

CCOc1ccc2nc3ccccc3cc2c1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
KDM4E B2RXH2 6/20 0.50
GAA P10253 3/20 0.50
TLR8 Q9NR97 1/20 0.50
PDE10A Q9Y233 2/20 0.48
LMNA P02545 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
TP53 P04637 1/20 0.46
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CXCR5 P32302 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503962 0.80 ALDH1A1 (0.61) ALDH1A1KDM4ELMNATP53RAB9A
SCHEMBL30393029 0.80 ALDH1A1 (0.61) ALDH1A1KDM4ELMNATP53RAB9A
Hydrochloric Acid SCHEMBL1037379 0.79 ALDH1A1 (0.60) ALDH1A1KDM4ELMNATP53RAB9A
SCHEMBL10751607 0.78 TLR8 (0.59) ALDH1A1KDM4EGAATLR8PDE10A
SCHEMBL16588903 0.77 TLR8 (0.59) ALDH1A1KDM4EGAATLR8LMNA
SCHEMBL27546694 0.77 PDE10A (0.49) ALDH1A1KDM4EGAAPDE10ALMNA
SCHEMBL27993510 0.76 ALOX15 (0.49) ALDH1A1KDM4EGAATLR8LMNA
SCHEMBL9422350 0.75 NPC1 (0.49) ALDH1A1KDM4EGAAPDE10ALMNA
SCHEMBL6532788 0.74 MAPT (0.48) ALDH1A1GAALMNARAB9ANPC1
SCHEMBL12471647 0.74 ALDH1A1 (0.45) ALDH1A1KDM4EGAAPDE10ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006040650-A1 4-METHOXYACRIDINE-1-CARBOXAMIDE DERIVATIVES AND THE PHENAZINE AND OXANTHRENE ANALOGS AS PDE4-INHIBITORS FOR THE TREATMENT OF ASTHMA AND CHRONIC PULMONARY DISEASE (COPD) GLENMARK PHARMACEUTICALS S.A. (US) 2006-04-20 WO disclosed